Key result
Discharge beta-blockers linked to ~23% lower 1-year mortality in elderly HF with LVSD.
Why the study?
Beta-blockers are guideline-recommended for heart failure, but their clinical effectiveness is not well-understood, especially in elderly patients.
Does newly initiated beta-blocker therapy at hospital discharge reduce 1-year mortality and all-cause rehospitalization in elderly patients hospitalized for heart failure with left ventricular systolic dysfunction or preserved systolic function?
Cohort (n=7,154)
Yes
Does newly initiated beta-blocker therapy at hospital discharge reduce 1-year mortality and all-cause rehospitalization in elderly patients hospitalized for heart failure with left ventricular systolic dysfunction or preserved systolic function?
In elderly patients hospitalized for heart failure, initiating beta-blocker therapy at discharge is associated with significantly lower 1-year mortality and combined mortality-rehospitalization in those with left ventricular systolic dysfunction, but offers no significant clinical benefit in those with preserved systolic function.
Answers are grounded in this paper and cite their sources.
Beta-blocker initiation at discharge was associated with lower mortality in elderly HF with LVSD but not preserved function; leaves open randomized confirmation before practice change.
Objectives We sought to examine associations between initiation of beta-blocker therapy and outcomes among elderly patients hospitalized for heart failure. Background Beta-blockers are guideline-recommended therapy for heart failure, but their clinical effectiveness is not well-understood, especially in elderly patients. Methods We merged Medicare claims data with OPTIMIZE-HF records to examine long-term outcomes of eligible patients newly initiated on beta-blocker therapy. We used inverse probability-weighted Cox proportional hazards models to determine the relationships between treatment and mortality, rehospitalization, and a combined mortality–rehospitalization endpoint. Results Observed 1-year mortality was 33%, and all-cause rehospitalization was 64%. Among 7154 patients hospitalized with heart failure and eligible for beta-blockers, 3421 (49%) were newly initiated on beta-blocker therapy. Among patients with left ventricular systolic dysfunction (LVSD; n = 3001), beta-blockers were associated with adjusted hazard ratios of 0.77 (95% confidence interval [CI], 0.68–0.87) for mortality, 0.89 (95% CI, 0.80–0.99) for rehospitalization, and 0.87 (95% CI, 0.79–0.96) for mortality–rehospitalization. Among patients with preserved systolic function (n = 4153), beta-blockers were associated with adjusted hazard ratios of 0.94 (95% CI, 0.84–1.07) for mortality, 0.98 (95% CI, 0.90–1.06) for rehospitalization, and 0.98 (95% CI, 0.91–1.06) for mortality-rehospitalization. Conclusions In elderly patients hospitalized with heart failure and LVSD, incident beta-blocker use was clinically effective and independently associated with lower risks of death and rehospitalization. Patients with preserved systolic function had poor outcomes, and beta-blockers did not significantly influence the mortality and rehospitalization risks for these patients.
No takes yet. Share an insight, caveat, or question.
Hernandez et al. (2009) conducted a cohort in Heart failure (n=7,154). Newly initiated beta-blocker therapy at hospital discharge vs. No beta-blocker therapy at hospital discharge was evaluated on 1-year mortality in patients with left ventricular systolic dysfunction (LVSD) (HR 0.77, 95% CI 0.68–0.87). Incident beta-blocker therapy at discharge reduced 1-year mortality in elderly heart failure patients with LVSD but not in preserved systolic function.
Synapse has enriched 10 related papers. Consider them for comparative context: